Eli Lilly is still best long-term growth story in large cap pharma despite messy quarter

on
The headline figures look fine, but things got rough with the outlook for the rest of 2022. Here's our analysis of Lilly (LLY) earnings.

from US Top News and Analysis https://ift.tt/hpSPw6D
https://ift.tt/y40dOFP

Comments

Post a Comment